Phenytoin Testing Market Press Release

1. Global Phenytoin Testing Market to be Propelled by Growing Incidents of PhenytoinToxicityandPreventiveCareofKidneyandCentralNervous System(CNS)by CAGRof~2%During2023–2033 Kenneth Research published a report titled “Phenytoin Testing Market: Global Demand Analysis & Opportunity Outlook 2033” which delivers detailed overview of the global phenytoin testing market in terms of market segmentation by product type, end-user andby region. Further,for thein-depthanalysis, thereportencompasses theindustry growth indicators,restraints,supplyanddemandrisk,alongwithdetaileddiscussiononcurrent and future markettrends thatareassociated withthegrowthofthemarket. The global phenytoin testing market is expected to hold a revenue of ~USD 8 billion by 2033, growing from ~USD 7 billion in 2022. The market growth can be attributed to the increase in the incidents of phenytoin toxicity, the relevance of the test in the preventive careofkidneyandCNS diseases, casesofepilepsyandpost-surgicalseizures,expansion

2. of services by key service providers, demand for point-of-care testing, and awareness aboutdrug abuseand drugadherence. TheglobalphenytointestingmarketisexpectedtogrowataCAGRofapproximately2% from 2023-2033. The market is segmented by end-user into hospitals, pathological laboratories,andresearchcenters.Ofthese,thehospitals'segmentisanticipatedtohold the largest market share by the end of 2033, owing to the increase in the number of hospitals worldwide and theconsiderabledevelopmentsinhealthcareinfrastructure. For moredescription@https://www.kennethresearch.com/report-details/phenytoin- testing-market/10352433 The global phenytoin testing market is divided into five major regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is projected to hold the largest market share by the end of 2033, backed bytheriseinthenumberofactiveepilepsycasesandthegrowthofpathologicallabsand health careinfrastructure. The research is global in nature and covers detailed analysis on the market in North America(U.S.,Canada),Europe(U.K.,Germany,France,Italy,Spain,Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest ofLatinAmerica),Asia-Pacific(China,India,Japan,SouthKorea,Indonesia,Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth&opportunityanalysis,marketplayers’competitivestudy,investment opportunities,demandforfutureoutlooketc.hasalsobeencoveredanddisplayedinthe researchreport. Significance in the Preventive Care of Kidney and CNS to Boost the Market Growth

3. AccordingtoareportonUremiabytheNationalCentreforBiotechnologyInformation (NCBI), about 354 people in a million are diagnosed with end-stage renal disease (ESRD) every year. Similarly, every year, more than 17 million people are thought to misuse prescription drugs,includingCNSdepressants. Phenytointoxicity inpatientsofepilepsy,especiallywhen thedrughas notbeen overused, indicates conditions of renal failure, including hypoalbuminemia and uremia. Thus, phenytoin testing is beneficial in the early detection of renal failure. As in the case of any other CNS depressants, the overuse of phenytoin puts a patient at risk of mental and physical issues and can even lead to death. So, the regular monitoring of phenytoin levels in thebloodcan prevent theadverseeffect ofphenytointoxicityontheCNS. However,inconsistent testresults,expensesrelatedtotheregularmonitoringof phenytoin levels,and theavailabilityofalternativesfor phenytoinareexpectedto operate as keyrestraintto thegrowthofglobalphenytointestingmarketoverthe forecastperiod. This report also provides the existing competitive scenario of some of the key players of the global phenytoin testing market which includes company profiling of Abbott, ARUP Laboratories, Quest Diagnostics Incorporated, Lybrate Inc., Portea Medical, Pfizer Inc., SunPharmaceuticalIndustriesLtd., RandoxLaboratoriesLtd.,Personalabs,Roche Diagnostics, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global phenytoin testing market that will help industry consultants, equipment manufacturers, existingplayerssearchingforexpansionopportunities, newplayerssearching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in thefuture. RequestReport Sample@https://www.kennethresearch.com/sample-request- 10352433

4. Kenneth Researchisaleading serviceproviderfor strategicmarketresearchand consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order toavoid futureuncertainties. ContactformoreInfo: AJDaniel Email:sales@kennethresearch.com U.S. Phone:+13134620609